中恆集團(600252.SH):耀勻醫藥將對成都金星增資約1.13億元
格隆匯11月15日丨中恆集團(600252.SH)公佈,近日,公司控股子公司重慶萊美藥業股份有限公司(“萊美藥業”)及控股孫公司成都金星健康藥業有限公司(“成都金星”、“目標公司”)、成都金星少數股東Sanum-Kehlbeck GmbH & Co.KG (“德國沙奴姆公司”)、成都耀勻醫藥科技有限公司(“耀勻醫藥”)對《成都金星健康藥業有限公司增資和認購協議》(“原擬簽署協議”)相關條款進行了細化和完善,並簽署了修訂後的協議。耀勻醫藥將對成都金星進行增資,增資金額為人民幣112,810,271.79元。
此次成都金星增資完成後,耀勻醫藥將持有目標公司61%股權、萊美藥業將持有目標公司35.1%股權、德國沙奴姆公司將持有目標公司3.9%股權,成都金星將不再納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.